Enhanced serotonin transporter function during depression in seasonal affective disorder

Neuropsychopharmacology

Volumn 33, Issue 7, 2008, Pages 1503-1513

  Willeit, Matthäus ^a,c   Sitte, Harald H ^a   Thierry, Nikolaus ^a   Michalek, Klaus ^a   Praschak Rieder, Nicole ^a   Zill, Peter ^b   Winkler, Dietmar ^a   Brannath, Werner ^a   Fischer, Michael B ^a   Bondy, Brigitta ^b   Kasper, Siegfried ^a   Singer, Ernst A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bright light therapy; Efflux; Outward transport; SAD; SERT; Tyramine

Indexed keywords

SEROTONIN TRANSPORTER; TYRAMINE;

ADULT; ARTICLE; BINDING AFFINITY; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; FEMALE; FOLLICULAR PHASE; GENOTYPE; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; MAJOR CLINICAL STUDY; MALE; MENSTRUAL CYCLE; PHOTOTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN TRANSPORT; RECEPTOR AFFINITY; RECEPTOR DENSITY; REMISSION; SEASONAL AFFECTIVE DISORDER; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; SEROTONIN UPTAKE; SUMMER; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; TURNOVER TIME; WHITE LIGHT;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ANALYSIS OF VARIANCE; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOTOTHERAPY; PLASMA; PSYCHIATRIC STATUS RATING SCALES; SEASONAL AFFECTIVE DISORDER; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STATISTICS, NONPARAMETRIC; TIME FACTORS; TYRAMINE;

EID: 43649109032     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301560     Document Type: Article

References (85)

1. Avery DH (1998). A turning point for seasonal affective disorder and light therapy research? Arch Gen Psychiatry 55: 863-864.
2. Axelrod J, Inscoe JK (1963). The uptake and binding of circulating serotonin and the effect of drugs. J Pharmacol Exp Ther 141: 161-165.
3. Carneiro AM, Blakely RD (2006). Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J Biol Chem 281: 24769-24780.
4. Cesura AM, Ritter A, Picotti GB, Da Prada M (1987). Uptake, release, and subcellular localization of 1-methyl-4-phenylpyridinium in blood platelets. J Neurochem 49: 138-145.
5. Chang AS, Chang SM (1999). Nongenomic steroidal modulation of high-affinity serotonin transport. Biochim Biophys Acta 1417: 157-166.
6. Cook Jr EH, Courchesne R, Lord C, Cox NJ, Yan S, Lincoln A et al (1997). Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry 2: 247-250.
7. Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal JH et al (1991). Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 27: 321-330.
8. 3H]paroxetine to platelets of depressed patients: seasonal differences and effects of diagnostic classification. J Affect Disord 32: 27-35.
9. DSM-IV (1994). Diagnostic and Statistical Manual of Mental Disorders 4th edn. American Psychiatric Association: Washington, DC.
10. Eastman CI, Young MA, Fogg LF, Liu L, Meaden PM (1998). Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry 55: 883-889.
11. First M, Gibbon M, Spitzer R, Williams J (1996). Structured Clinical Interview for DSM-IV Axis I Disorders: Nonpatient Edition (SCID-I/NP). Biometrics Research Department, New York State Psychiatric Institute: New York, NY.
12. Fischer JF, Cho AKY (1979). Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 208: 203-209.
13. Fog JU, Khoshbouei H, Holy M, Owens WA, Vaegter CB, Sen N et al (2006). Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51: 417-429.
14. Franke L, Schewe HJ, Muller B, Campman V, Kitzrow W, Uebelhack R et al (2000). Serotonergic platelet variables in unmedicated patients suffering from major depression and healthy subjects: relationship between 5HT content and 5HT uptake. Life Sci 67: 301-305.
15. Franke L, Schewe HJ, Uebelhack R, Muller-Oerlinghausen B (2003). High platelet-serotonin uptake activity is associated with a rapid response in depressed patients treated with amitriptyline. Neurosci Lett 345: 105-108.
16. Garcia-Borreguero D, Jacobsen FM, Murphy DL, Joseph-Vanderpool JR, Chiara A, Rosenthal NE (1995). Hormonal responses to the administration of m-chlorophenylpiperazine in patients with seasonal affective disorder and controls. Biol Psychiatry 37: 740-749.
17. Gobbi M, Moia M, Pirona L, Ceglia I, Reyes-Parada M, Scorza C et al (2002). p-Methylthioamphetamine and 1-(m-chlorophenyl) piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro. J Neurochem 82: 1435-1443.
18. Greenberg BD, Tolliver TJ, Huang SJ, Li Q, Bengel D, Murphy DL (1999). Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 88: 83-87.
19. Gu H, Wall SC, Rudnick G (1994). Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269: 7124-7130.
20. Hahn MK, Mazei-Robison MS, Blakely RD (2005). Single nucleotide polymorphisms in the human norepinephrine transporter gene affect expression, trafficking, antidepressant interaction, and protein kinase C regulation. Mol Pharmacol 68: 457-466.
21. Hahn MK, Robertson D, Blakely RD (2003). A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci 23: 4470-4478.
22. Hale AS, Sandler M, Hannah P, Bridges PKY (1989). Tyramine conjugation test for prediction of treatment response in depressed patients. Lancet 1: 234-236.
23. Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278-296.
24. Harrison WM, Cooper TB, Stewart JW, Quitkin FM, McGrath PJ, Liebowitz MR et al (1984). The tyramine challenge test as a marker for melancholia. Arch Gen Psychiatry 41: 681-685.
25. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D et al (1996). Allelic variation of human serotonin transporter gene expression. J Neurochem 66: 2621-2624.
26. Hilber B, Scholze P, Dorostkar MM, Sandtner W, Holy M, Boehm S et al (2005). Serotonin-transporter mediated efflux: a pharmacological analysis of amphetamines and non-amphetamines. Neuropharmacology 49: 811-819.
27. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985). Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173-2177.
28. Javors MA, Seneviratne C, Roache JD, Ait-Daoud N, Bergeson SE, Walss-Bass MC et al (2005). Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics. Prog Neuropsychopharmacol Biol Psychiatry 29: 7-13.
29. Jayanthi LD, Samuvel DJ, Blakely RD, Ramamoorthy S (2005). Evidence for biphasic effects of protein kinase C on serotonin transporter function, endocytosis, and phosphorylation. Mol Pharmacol 67: 2077-2087.
30. Johansson C, Willeit M, Levitan R, Partonen T, Smedh C, Del Favero J et al (2003). The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality. Psychol Med 33: 785-792.
31. Kasper S (1991). Jahreszeit und Befindlichkeit in der Allgemein bevölkerung. Eine Mehrebenenuntersuchung zur Epidemiologie, Biologie und therapeutischen Beeinflussbarkeit (Lichttherapie) saisonaler Befindlichkeitsschwankungen. In: Hippius H, Janzarik W, Müller C (eds). Monographien aus dem Gesamtgebiete der Psychiatrie. Springer Verlag: New York. pp 135-136.
32. Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME et al (2004). N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2: E78.
33. Kilic F, Murphy DL, Rudnick G (2003). A human serotonin transporter mutation causes constitutive activation of transport activity. Mol Pharmacol 64: 440-446.
34. Lam RW, Levitt AJ, Levitan RD, Enns MW, Morehouse R, Michalak EE et al (2006). The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 163: 805-812.
35. Lam RW, Zis AP, Grewal A, Delgado PL, Charney DS, Krystal JH (1996). Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy. Arch Gen Psychiatry 53: 41-44.
36. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
37. Lesch KP, Wolozin BL, Murphy DL, Reiderer P (1993). Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 60: 2319-2322.
38. Levitan RD, Kaplan AS, Brown GM, Vaccarino FJ, Kennedy SH, Levitt AJ et al (1998). Hormonal and subjective responses to intravenous m-chlorophenylpiperazine in women with seasonal affective disorder. Arch Gen Psychiatry 55: 244-249.
39. Lewy AJ, Bauer VK, Cutler NL, Sack RL, Ahmed S, Thomas KH et al (1998). Morning vs evening light treatment of patients with winter depression. Arch Gen Psychiatry 55: 890-896.
40. Lim JE, Papp A, Pinsonneault J, Sadee W, Saffen D (2006). Allelic expression of serotonin transporter (SERT) mRNA in human pons: lack of correlation with the polymorphism SERTLPR. Mol Psychiatry 11: 649-662.
41. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L et al (1998). Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane and single photon emission computed tomography. Biol Psychiatry 44: 1090-1098.
42. Maswood S, Truitt W, Hotema M, Caldarola-Pastuszka M, Uphouse L (1999). Estrous cycle modulation of extracellular serotonin in mediobasal hypothalamus: role of the serotonin transporter and terminal autoreceptors. Brain Res 831: 146-154.
43. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N et al (2004). Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 61: 1271-1279.
44. Moscovitch A, Blashko CA, Eagles JM, Darcourt G, Thompson C, Kasper S et al (2004). A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl) 171: 390-397.
45. Nass R, Hahn MK, Jessen T, McDonald PW, Carvelli L, Blakely RD (2005). A genetic screen in Caenorhabditis elegans for dopamine neuron insensitivity to 6-hydroxydopamine identifies dopamine transporter mutants impacting transporter biosynthesis and trafficking. J Neurochem 94: 774-785.
46. Neuger J, El Khoury A, Kjellman BF, Wahlund B, Aberg-Wistedt A, Stain-Malmgren R (1999). Platelet serotonin functions in untreated major depression. Psychiatry Res 85: 189-198.
47. Neumeister A, Praschak-Rieder N, Besselmann B, Rao ML, Gluck J, Kasper S (1997). Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during a stable response to bright light therapy. Arch Gen Psychiatry 54: 133-138.
48. Neumeister A, Praschak-Rieder N, Hesselmann B, Vitouch O, Rauh M, Barocka A et al (1998). Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. Psychol Med 28: 257-264.
49. Nisimura T, Seto A, Nakamura K, Miyama M, Nagao T, Tamotsu S et al (2005). Experiential effects of appetitive and nonappetitive odors on feeding behavior in the blowfly, Phormia regina: a putative role for tyramine in appetite regulation. J Neurosci 25: 7507-7516.
50. Nobile M, Begni B, Giorda R, Frigerio A, Marino C, Molteni M et al (1999). Effects of serotonin transporter promoter genotype on platelet serotonin transporter functionality in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 38: 1396-1402.
51. Owens MJ, Nemeroff CB (1994). Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40: 288-295.
52. 3H]paroxetine binding, 5-HT-stimulated Ca2+ response, and 5-HT content in winter seasonal affective disorder. Biol Psychiatry 36: 458-466.
53. Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J et al (2006). Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 163: 52-58.
54. Partonen T, Lonnqvist J (2000). Bright light improves vitality and alleviates distress in healthy people. J Affect Disord 57: 55-61.
55. 3H]paroxetine to the platelet serotonin transporter sites in African-American cocaine-dependent patients and healthy volunteers. Hum Psychopharmacol 18: 103-111.
56. Pifl C, Singer EA (1999). Ion dependence of carrier-mediated release in dopamine or norepinephrine transporter-transfected cells questions the hypothesis of facilitated exchange diffusion. Mol Pharmacol 56: 1047-1054.
57. Prasad HC, Zhu CB, McCauley JL, Samuvel DJ, Ramamoorthy S, Shelton RC et al (2005). Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Proc Natl Acad Sci 102: 11545-11550.
58. Quick MW (2003). Regulating the conducting states of a mammalian serotonin transporter. Neuron 40: 537-549.
59. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS et al (1993). Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci 90: 2542-2546.
60. Rausch JL, Johnson ME, Li J, Hutcheson J, Carr BM, Corley KM et al (2005). Serotonin transport kinetics correlated between human platelets and brain synaptosomes. Psychopharmacology (Berl) 180: 391-398.
61. 3H]paroxetine binding sites in platelets from depressed patients. J Affect Disord 52: 225-233.
62. Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y et al (1984). Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 41: 72-80.
63. Rothman RB, Baumann MH (2002). Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95: 73-88.
64. Rudnick G, Clark J (1993). From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144: 249-263.
65. Sandler M, Carter SB, Cuthbert MF, Pare CMY (1975). Is there an increase in monoamine-oxidase activity in depressive illness? Lancet 1: 1045-1049.
66. Scholze P, Sitte HH, Singer EAY (2001). Substantial loss of substrate by diffusion during uptake in HEK-293 cells expressing neurotransmitter transporters. Neurosci Lett 309: 173-176.
67. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH (2000). Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther 293: 870-878.
68. Schuemann HJ (1960). On the liberation of pyrocatecholamines by tyramine. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 238: 41-43.
69. Schwartz PJ, Murphy DL, Wehr TA, Garcia-Borreguero D, Oren DA, Moul DE et al (1997). Effects of meta-chlorophenylpiperazine infusions in patients with seasonal affective disorder and healthy control subjects. Diurnal responses and nocturnal regulatory mechanisms. Arch Gen Psychiatry 54: 375-385.
70. Seidel S, Singer EA, Just H, Farhan H, Scholze P, Kudlacek O et al (2005). Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action. Mol Pharmacol 67: 140-151.
71. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I et al (2000). Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 342: 541-549.
72. Sitte HH, Farhan H, Javitch JA (2004). Sodium-dependent neurotransmitter transporters: oligomerization as a determinant of transporter function and trafficking. Mol Interv 4: 38-47.
73. Sitte HH, Hiptmair B, Zwach J, Pifl C, Singer EA, Scholze P (2001). Quantitative analysis of inward and outward transport rates in cells stably expressing the cloned human serotonin transporter: inconsistencies with the hypothesis of facilitated exchange diffusion. Mol Pharmacol 59: 1129-1137.
74. 3H]lysergic acid diethylamide binding in seasonal affective disorder and the effect of bright light therapy. Biol Psychiatry 45: 464-470.
75. Smith KA, Fairburn CG, Cowen PJ (1997). Relapse of depression after rapid depletion of tryptophan. Lancet 349: 915-919.
76. Stain-Malmgren R, Kjellman BF, Aberg-Wistedt A (1998). Platelet serotonergic functions and light therapy in seasonal affective disorder. Psychiatry Res 78: 163-172.
77. Staley JK, Sanacora G, Tamagnan G, Maciejewski PK, Malison RT, Berman RM et al (2006). Sex differences in diencephalon serotonin transporter availability in major depression. Biol Psychiatry 59: 40-47.
78. Stewart JW, Harrison W, Cooper TB, Quitkin FMY (1988). Tyramine sulfate excretion may be a better predictor of antidepressant response than monoamine oxidase activity. Psychiatry Res 25: 195-201.
79. Swiecicki L, Bidzinski A, Tonderska A (2005). [Platelet serotonin transport in the group of outpatients with seasonal affective disorder before and after light treatment, and in remission (in the summer)]. Psychiatr Pol 39: 459-468.
80. Terman M, Terman JS, Ross DC (1998). A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry 55: 875-882.
81. Weissman MM, Wickramaratne P, Adams P, Wolk S, Verdeli H, Olfson M (2000). Brief screening for family psychiatric history: the family history screen. Arch Gen Psychiatry 57: 675-682.
82. Willeit M, Praschak-Rieder N, Neumeister A, Pirker W, Asenbaum S, Vitouch O et al (2000). [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry 47: 482-489.
83. Willeit M, Praschak-Rieder N, Neumeister A, Zill P, Leisch F, Stastny J et al (2003). A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. Mol Psychiatry 8: 942-946.
84. Williams JD, Link MJ, Rosenthal NE, Terman M (1988). Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorder Version (SIGH-SAD). New York Psychiatric Institute: New York.
85. Wirz-Justice A (1998). Beginning to see the light. Arch Gen Psychiatry 55: 861-862.